• Home
  • Search Results

Research Studies

UNC-Chapel Hill Lineberger Comprehensive Cancer Center

242 studies match your search
Coming Soon

Study of AUTX-007 for Leukemia

The purpose of the study is to find out is AUTX-007 an investigational drug, can help treat or cure cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck)
Coming Soon

QuantifyHER

This trial will follow approximately 200 patients with HER2-low (IHC<2+) MBC who are starting T-DXd. The study will test a newly developed test to measure HER2 protein on tumor cells using an antibody that 'lights up' when attached to HER2. The 'light' is called fluorescence. Cells with HER2 light up when viewed under a microscope with a special light. The fluorescence strength matches with the amount of HER2 protein on the breast cancer cell. We propose to prove this test works in patients with MBC that is HER2 low (IHC<2+) and who are beginning treatment with T-DXd. Each patient in this study will have their tumor tested using this new fluorescence test (Quantitative Immunofluorescence, or QIF). Patients will be followed for response to T-DXd. We will compare the QIF score with IHC score as they relate to patients who benefit from T-DXd. We propose that QIF will more reliably tell

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Visit Location
100% Remote (online, phone, text)
Coming Soon

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Early-Stage Breast Cancer

The purpose of this study is to compare the usual treatment with hormonal therapy medications to treatment with low-dose tamoxifen. This study will help the study doctors find out if this different approach is the same as the usual approach. To decide if it is better, the study doctors will be looking to see if low-dose tamoxifen has the same chance of preventing breast cancer from returning compared to the usual hormonal therapy medications with less side effects

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Breast)
  • Women's Health
Coming Soon

The FoRtitude Interview Study

The goal of this research study is to interview breast cancer survivors who self-identify as Black/African American to obtain feedback and suggestions on refining the FoRtitude 2.0 eHealth intervention.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Breast)
  • Women's Health
Visit Location
100% Remote (online, phone, text)
Coming Soon

Ovarian Cancer Treatment

In this study, we want to find out if a medicine called Olaparib works as well as the usual treatment for ovarian cancer. We also want to see if this medicine can help stop the cancer from growing or coming back.

Age & Gender
  • 18 years ~ 99 years
  • Female, Gender Inclusive
Study Interest
  • Cancer (Uterine (endometrial), Ovarian)
  • Women's Health
Coming Soon

A Study of YL201 in Patients With Advanced Solid Tumors

This is a study of an investigational drug called YL201 as a possible treatment for advanced solid tumors. YL201 is thought to work by interrupting DNA replication in cancer cells, via focused delivery of the cytotoxic agent to the cancer cell. YL201 has shown some anti-cancer effects against cancer cells in the laboratory and in experimental animals. The main purpose of this study is to learn how safe the study drug and how well the study drug works.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck, Lung)
Coming Soon

PROGRESS: Precision Oncology using Genomic Reflexive Evaluations for Study Selection and Survival

The purpose of this research study is to look at a program that includes expert review of your tumor genetic test results. We want to see if this program can help your doctor identify better treatments or suitable clinical trials for your cancer. This is a hybrid decentralized study where some if not all assessments may be performed remotely or close to your home.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Breast, Colorectal, Lung)
Coming Soon

Combination of XL092 and Cemiplimab in Anaplastic Thyroid Cancer

The purpose of this study is to look at the effectiveness of giving cemiplimab and XL092 before and after surgery for Anaplastic Thyroid Cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Thyroid and Other Gland/Endocrine)
Not currently enrolling

Little Cigar and Cigarillo Use Study

We are doing a study to develop effective messages for social media campaigns to reduce the use of little cigars and cigarillos by young adults.

Age & Gender
  • 18 years ~ 29 years
  • Male, Female, Gender Inclusive
Study Interest
  • Substance Use (tobacco, alcohol, opioids, etc)
Visit Location
100% Remote (online, phone, text)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research